- Home
- OKYO vs LEXX Comparison
OKYO vs LEXX Comparison
Compare OKYO & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OKYO
- LEXX
- Stock Information
- Founded
- OKYO 2007
- LEXX 2004
- Country
- OKYO United Kingdom
- LEXX Canada
- Employees
- OKYO N/A
- LEXX N/A
- Industry
- OKYO Biotechnology: Biological Products (No Diagnostic Substances)
- LEXX Biotechnology: Pharmaceutical Preparations
- Sector
- OKYO Health Care
- LEXX Health Care
- Exchange
- OKYO Nasdaq
- LEXX Nasdaq
- Market Cap
- OKYO 38.6M
- LEXX 39.1M
- IPO Year
- OKYO 2022
- LEXX N/A
- Fundamental
- Price
- OKYO $1.02
- LEXX $2.02
- Analyst Decision
- OKYO Strong Buy
- LEXX Strong Buy
- Analyst Count
- OKYO 1
- LEXX 2
- Target Price
- OKYO $7.00
- LEXX $11.00
- AVG Volume (30 Days)
- OKYO 89.8K
- LEXX 140.3K
- Earning Date
- OKYO 01-28-2025
- LEXX 01-10-2025
- Dividend Yield
- OKYO N/A
- LEXX N/A
- EPS Growth
- OKYO N/A
- LEXX N/A
- EPS
- OKYO N/A
- LEXX N/A
- Revenue
- OKYO N/A
- LEXX $496,923.00
- Revenue This Year
- OKYO N/A
- LEXX $20.39
- Revenue Next Year
- OKYO N/A
- LEXX $113.25
- P/E Ratio
- OKYO N/A
- LEXX N/A
- Revenue Growth
- OKYO N/A
- LEXX 77.63
- 52 Week Low
- OKYO $0.81
- LEXX $1.36
- 52 Week High
- OKYO $1.90
- LEXX $6.85
- Technical
- Relative Strength Index (RSI)
- OKYO 42.56
- LEXX 39.89
- Support Level
- OKYO $1.00
- LEXX $1.62
- Resistance Level
- OKYO $1.35
- LEXX $2.43
- Average True Range (ATR)
- OKYO 0.09
- LEXX 0.21
- MACD
- OKYO -0.01
- LEXX -0.02
- Stochastic Oscillator
- OKYO 5.71
- LEXX 44.99
About OKYO OKYO Pharma Limited
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
About LEXX Lexaria Bioscience Corp.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.